Limerick BioPharma Secures $15,000,000 Series C Financing

  • Feed Type
  • Date
  • Company Name
    Limerick BioPharma
  • Mailing Address
    601 Gateway Blvd. South San Francisco, CA 94080
  • Company Description
    Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients’ lives. Our compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug’s desired effects. In the monotherapy setting, we are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    OVP Venture Partners
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Sevin Rosen Funds
  • Venture Investor
    Altitude Life Science Ventures

Trending on Xconomy